跳至主要内容
临床试验/NCT05402397
NCT05402397已完成4 期

Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail

Hospital General de Niños Pedro de Elizalde1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2022年7月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
40
试验地点
1
主要终点
Serum uric acid levels after losartan treatment

研究概览

简要总结

The aim of this study is to assess the serum uric-acid lowering effect of losartan in children with proteinuric nephropathies. Patients already treated with enalapril will be randomized to receive losartan and/or enalapril in a cross-over designed study. Those who recruit the inclusion criteria will receive enalapril and/or losartan during a one month period, followed by a 15 days of wash out (under enalapril treatment). On day 46, the second period of 30 days of treatment start (enalapril or losartan, whichever was not received initially). Before randomization, a baseline 24 hours urine and a fasting blood sample will be obtained to assess uric acid excretion and serum uric acid values along with renal function and electrolyte levels. Then, similar determinations will be performed at days 30, 46 and 76.

详细描述

The working hypothesis is that the administration to losartan reduces significantly the serum uric acid levels in normotensive children with proteinuric nephropathies. The study will consist in a single center cross-over randomized, open label, clinical trial.

Inclusion criteria will be:children with poteinuric nephropathies already treated with enalapril under our care, age between 3 and 12 years and normal blood pressure.

Subjects will be selected by simple probability sampling and after the signature of the assent/informed consent, they will be randomized (blocks of 4 patients, treatment sequence 2:2) to receive a two phases regime of drugs: 1) arm enalapril-losartan, or 2) arm losartan-enalapril. Between phases there will be a 14 days wash out period (during this time patients will continue receiving enalapril, as this drug does not have effect on uric acid metabolism). The dose of enalapril will be that they usually receive, while the dose of losartan will be 5 times the those of enalapril that they usually receive.

Visit Schedule: day 1 (randomization) and 30 for the first drug; 15 days wash out period, day 46 and 76 for the second drug. In each visit a physical examination and blood pressure monitor will be performed, along with the following laboratory parameters: urea, creatinine, electrolytes, uric acid, glycemia, triglycerides, cholesterol and lipopolysaccharides. Simultaneously, in a spot urine morning sample will be determined the levels of uric acid, creatinine, proteinuria y albuminuria.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
3 Years 至 12 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Children with poteinuric nephropathies already treated with enalapril under our care.
  • Age between 3 and 12 years.
  • Normal blood pressure.

排除标准

  • Patients with high blood pressure.
  • Post menarche female patients.
  • Patients with hypouricemia (< 2 mg/dL).
  • Patients treated with diuretics.
  • Patients with absolute or relative contraindications to receive RAAS antagonists (glomerular filtration < 30 ml/min/1,73 m2, serum potassium > 5,5 mEq/L).
  • Patients with active rheumatic diseases.
  • Patients treated with dual blockade of the RAAS (enalapril +losartan).
  • Patients treated with calcineurin inhibitors.

研究组 & 干预措施

Enalapril

Active Comparator

Children with proteinuric nephropathies will receive enalapril prior or after a losartan period, according to randomization sequence.

Enalapril will be given at a dose between 0.1 to 0.4 mg/kg/day (according to the dose that they usually receive), once a day.

干预措施: Losartan Potassium (Drug)

Losartan

Experimental

Children with proteinuric nephropathies will receive losartan prior or after a enalapril period, according to randomization sequence.

Losartan will be given at a dose 5 times the dose of enalapril that they usually receive, (with a maximum dose of 1.4 mg/kg/day), once a day.

干预措施: Losartan Potassium (Drug)

结局指标

主要结局

Serum uric acid levels after losartan treatment

时间窗: 30 days

Patiens will receive a losartan regime after serum uric acid levels will be assessed

次要结局

  • Urinary uric acid levels after losartan treatment(30 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Alejandro Balestracci

Staff Nephrology Unit Hospital General de Niños Pedro de Elizalde

Hospital General de Niños Pedro de Elizalde

研究点 (1)

Loading locations...

相似试验